NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Probiotics and Insulin Resistance in Obese Asthmatics
Probiotics and Insulin Resistance in Obese Asthmatics

NCT05949255

Active Not RecruitingNA

Sponsor: University of Alabama at Birmingham

Conditions: Asthma, Obesity, Insulin Resistance

Interventions: Probiotic, Placebo

Countries: United States

In this pilot study investigators will test the hypothesis that administration of oral probiotics modulates microbiome/metabolome, lowers leptin and insulin resistance and improves clinical parameters of asthma in obese insulin resistant asthmatics. Preliminary studies with oral probiotic administration in obese asthmatics showed increased abundance of probiotics-derived Bifidobacterium species and Bifidobacterium-derived metabolite in the airways of asthmatics. Additionally, neutrophils and IL-17 producing Th17 cells were significantly reduced following probiotics administration. Based on these preliminary studies, the investigators propose to test the following aims: Specific Aim 1: Determine if probiotic administration modulates airway microbiome/metabolome in obese insulin resistant asthmatics Specific Aim 2: Determine if modulation of leptin levels and insulin sensitivity by probiotics administration correlates with airway metabolome alterations and weight loss in obese insulin resistant asthmatics Specific Aim 3: Determine if microbiome/metabolome changes in probiotics group correlates with changes in asthma biomarkers and improved clinical outcomes compared to placebo in obese insulin resistant asthmatics.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
InclusionCriteria:

* Age \> 18 years
* All patients will be obese asthmatics. Patients will have a body mass index \>30 and insulin resistance\>5.
* Asthmatics who have stable disease without changes to their asthma related medications for 3 months prior to enrollment

Exclusion Criteria:

* Asthma related hospitalization within 90 days of enrollment
* Asthma exacerbation requiring \>3 days of oral corticosteroids within 28 days of enrollment
* Comorbid lung diseases other than asthma
* Pregnancy or planned pregnancy
* Inability to understand study procedures and/or provide informed consent
* Other significant medical conditions based on discretion of PI
Locations (1)
  • Birmingham, Alabama, United States